Reducing the Risk of Sudden Death in Heart Failure With β-Blockers

Journal of Cardiac Failure

Volumn 12, Issue 9, 2006, Pages 734-746

  Adamson, Philip B ^a   Gilbert, Edward M ^b  

^a Oklahoma Heart Hospital   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic antagonists; Heart failure; Sudden death; Ventricular arrhythmias

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOFETILIDE; ENALAPRIL; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; NORADRENALIN; PROPRANOLOL; RAMIPRIL; SOTALOL; TRANDOLAPRIL;

ARTIFICIAL HEART PACEMAKER; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE ASSOCIATION; FATALITY; HEART ARRHYTHMIA; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; QT INTERVAL; REVIEW; RISK REDUCTION; SUDDEN DEATH; SYMPATHETIC TONE; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIA; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR REMODELING;

EID: 33845428435     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.08.213     Document Type: Review

References (123)

1. American Heart Association. Heart Disease and Stroke Statistics-2006 Update (2006), American Heart Association, Dallas, TX
2. Ho K.K.L., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 (1993) 107-115
3. Goldman S., Johnson G., Cohn J.N., Cintron G., Smith R., and Francis G. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. Circulation 87 (1993) VI24-VI31
4. Narang R., Cleland J.G., Erhardt L., Ball S.G., Coats A.J., Cowley A.J., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17 (1996) 1390-1403
5. Kannel W.B., Plehn J.F., and Cupples L.A. Cardiac failure and sudden death in the Framingham Study. Am Heart J 115 (1988) 869-875
6. Hinkle Jr. L.E., and Thaler H.T. Clinical classification of cardiac deaths. Circulation 65 (1982) 457-464
7. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
8. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
9. Kempf Jr. F.C., and Josephson M.E. Cardiac arrest recorded on ambulatory electrocardiograms. Am J Cardiol 53 (1984) 1577-1582
10. Savage H.R., Kissane J.Q., Becher E.L., Maddocks W.Q., Murtaugh J.T., and Dizadji H. Analysis of ambulatory electrocardiograms in 14 patients who experienced sudden cardiac death during monitoring. Clin Cardiol 10 (1987) 621-632
11. Bayes de Luna A., Coumel P., and Leclercq J.F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117 (1989) 151-159
12. Keefe D.L., Schwartz J., and Somberg J.C. The substrate and the trigger: the role of myocardial vulnerability in sudden cardiac death. Am Heart J 113 (1987) 218-225
13. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 85 (1992) I2-I10
14. Tomaselli G.F., and Rose J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol 15 (2000) 202-208
15. Vermeulen J.T., McGuire M.A., Opthof T., Coronel R., de Bakker J.M., Klopping C., et al. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res 28 (1994) 1547-1554
16. Näbauer M., Beuckelmann D.J., Überfuhr P., and Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 93 (1996) 168-177
17. Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace 2 (2000) 216-223
18. Kawara T., Derksen R., de Groot J.R., Coronel R., Tasseron S., Linnenbank A.C., et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 104 (2001) 3069-3075
19. Maheshwari V.D., and Girish M.P. QT dispersion as a marker of left ventricular mass in essential hypertension. Indian Heart J 50 (1998) 414-417
20. Rials S.J., Wu Y., Ford N., Pauletto F.J., Abramson S.V., Rubin A.M., et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 91 (1995) 426-430
21. Wu T.J., Ong J.J., Hwang C., Lee J.J., Fishbein M.C., Czer L., et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 32 (1998) 187-196
22. Dinerman J.L., Berger R., Haigney M.C., Lawrence J.H., Tomaselli G.F., and Calkins H. Dispersion of ventricular activation and refractoriness in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 79 (1997) 970-974
23. Kimura S., Bassett A.L., Cameron J.S., Huikuri H., Kozlovskis P.L., and Myerburg R.J. Cellular electrophysiological changes during ischemia in isolated, coronary-perfused cat ventricle with healed myocardial infarction. Circulation 78 (1988) 401-406
24. Mann D.L. Basic mechanisms of left ventricular remodeling: the contribution of wall stress. J Card Fail 10 (2004) S202-S206
25. Cardinal R., Vermeulen M., Shenasa M., Roberge F., Page P., Helie F., et al. Anisotropic conduction and functional dissociation of ischemic tissue during reentrant ventricular tachycardia in canine myocardial infarction. Circulation 77 (1988) 1162-1176
26. de Bakker J.M., Coronel R., Tasseron S., Wilde A.A., Opthof T., Janse M.J., et al. Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 15 (1990) 1594-1607
27. Butrous G.S., Gough W.B., Restivo M., Yang H., and El Sherif N. Adrenergic effects on reentrant ventricular rhythms in subacute myocardial infarction. Circulation 86 (1992) 247-254
28. Kammerling J.J., Green F.J., Watanabe A.M., Inoue H., Barber M.J., Henry D.P., et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 76 (1987) 383-393
29. Dambrink J.H., Beukema W.P., van Gilst W.H., Peels K.H., Lie K.I., and Kingma J.H. Left ventricular dilatation and high-grade ventricular arrhythmias in the first year after myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. J Card Fail 1 (1994) 3-11
30. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., and Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
31. Dambrink J.H., SippensGroenewegen A., van Gilst W.H., Peels K.H., Grimbergen C.A., and Kingma J.H. Association of left ventricular remodeling and nonuniform electrical recovery expressed by nondipolar QRST integral map patterns in survivors of a first anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. Circulation 92 (1995) 300-310
32. Adamson P.B., Barr R.C., Callans D.J., Chen P.S., Lathrop D.A., Makielski J.C., et al. The perplexing complexity of cardiac arrhythmias: beyond electrical remodeling. Heart Rhythm 2 (2005) 650-659
33. Adamson P.B., and Vanoli E. Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure: characteristics of a novel heart failure model in dogs with postmyocardial infarction left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1741-1748
34. Adamson P.B., Huang M.H., Vanoli E., Foreman R.D., Schwartz P.J., and Hull Jr. S.S. Unexpected interaction between beta-adrenergic blockade and heart rate variability before and after myocardial infarction. A longitudinal study in dogs at high and low risk for sudden death. Circulation 90 (1994) 976-982
35. Swann M.H., Nakagawa H., Vanoli E., Lazzara R., Schwartz P.J., and Adamson P.B. Heterogeneous regional endocardial repolarization is associated with increased risk for ischemia-dependent ventricular fibrillation after myocardial infarction. J Cardiovasc Electrophysiol 14 (2003) 873-879
36. Billman G.E., Schwartz P.J., and Stone H.L. The effects of daily exercise on susceptibility to sudden cardiac death. Circulation 69 (1984) 1182-1189
37. Schwartz P.J., Vanoli E., Stramba-Badiale M., De Ferrari G.M., Billman G.E., and Foreman R.D. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 78 (1988) 969-979
38. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 (2004) 754-763
39. Chen P.S., Chen L.S., Cao J.M., Sharifi B., Karagueuzian H.S., and Fishbein M.C. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res 50 (2001) 409-416
40. La Rovere M.T., Bigger Jr. J.T., Marcus F.I., Mortara A., and Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351 (1998) 478-484
41. Fei L., Anderson M.H., Katritsis D., Sneddon J., Statters D.J., Malik M., et al. Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease. Br Heart J 71 (1994) 16-21
42. Gilbert E.M., and Port J.D. Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. Curr Cardiol Rep 2 (2000) 225-232
43. Billman G.E., Castillo L.C., Hensley J., Hohl C.M., and Altschuld R.A. Beta 2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 96 (1997) 1914-1922
44. Zhang Z.S., Cheng H.J., Ukai T., Tachibana H., and Cheng C.P. Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure. J Pharmacol Exp Ther 298 (2001) 188-196
45. Koumi S., Backer C.L., Arentzen C.E., and Sato R. Beta-adrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myocytes. Alteration in channel response to beta-adrenergic stimulation in failing human hearts. J Clin Invest 96 (1995) 2870-2881
46. Kurokawa J., Chen L., and Kass R.S. Requirement of subunit expression for cAMP-mediated regulation of a heart potassium channel. Proc Natl Acad Sci U S A 100 (2003) 2122-2127
47. Volders P.G., Stengl M., van Opstal J.M., Gerlach U., Spatjens R.L., Beekman J.D., et al. Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation. Circulation 107 (2003) 2753-2760
48. Zhang L.M., Wang Z., and Nattel S. Effects of sustained beta-adrenergic stimulation on ionic currents of cultured adult guinea pig cardiomyocytes. Am J Physiol Heart Circ Physiol 282 (2002) H880-H889
49. Thomas D., Kiehn J., Katus H.A., and Karle C.A. Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel. Basic Res Cardiol 99 (2004) 279-287
50. Anderson K.P. Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances. Ann Noninvasive Electrocardiol 1908 (2003) 75-89
51. Meszaros J., Ryder K.O., and Hart G. Transient outward current in catecholamine-induced cardiac hypertrophy in the rat. Am J Physiol 271 (1996) H2360-H2367
52. Pacioretty L.M., and Gilmour Jr. R.F. Restoration of transient outward current by norepinephrine in cultured canine cardiac myocytes. Am J Physiol 275 (1998) H1599-H1605
53. Han X., and Ferrier G.R. Contribution of Na(+)-Ca2+ exchange to stimulation of transient inward current by isoproterenol in rabbit cardiac Purkinje fibers. Circ Res 76 (1995) 664-674
54. Pogwizd S.M., Schlotthauer K., Li L., Yuan W., and Bers D.M. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88 (2001) 1159-1167
55. Lu T., Lee H.C., Kabat J.A., and Shibata E.F. Modulation of rat cardiac sodium channel by the stimulatory G protein alpha subunit. J Physiol 518 (1999) 371-384
56. Murphy B.J., Rogers J., Perdichizzi A.P., Colvin A.A., and Catterall W.A. cAMP-dependent phosphorylation of two sites in the alpha subunit of the cardiac sodium channel. J Biol Chem 271 (1996) 28837-28843
57. Yarbrough T.L., Lu T., Lee H.C., and Shibata E.F. Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. Circ Res 90 (2002) 443-449
58. Hoppe U.C., Jansen E., Sudkamp M., and Beuckelmann D.J. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation 97 (1998) 55-65
59. Kimura S., Bassett A.L., Kohya T., Kozlovskis P.L., and Myerburg R.J. Automaticity, triggered activity, and responses to adrenergic stimulation in cat subendocardial Purkinje fibers after healing of myocardial infarction. Circulation 75 (1987) 651-660
60. Bourke M. Cardiac Electrophysiology and Arrhythmias. Cardiovascular Core Program, University of Ottawa Heart Institute, Ottawa, Ontario; 2002.
61. Lombardi W.L., and Gilbert E.M. Carvedilol in the failing heart. Clin Cardiol 24 (2001) 757-766
62. Baker J.G., Hall I.P., and Hill S.J. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64 (2003) 1357-1369
63. Miller J.M., and Zipes D.P. Therapy for cardiac arrhythmias. In: Zipes D.P., Libby P., Bonow R.O., and Braunwald E. (Eds). Braunwald's heart disease. Ed. 7 (2005), Elsevier Saunders, Philadelphia, PA 713-766
64. Mesquita E.T., de Deus F.C., Guedes C.R., Maia E.R., Subieta C.G., Villacorta H., et al. Effects of propranolol on the QT dispersion in congestive heart failure. [in Portuguese]. Arq Bras Cardiol 73 (1999) 291-298
65. Barrington P.L., and Ten Eick R.E. Characterization of the electrophysiological effects of metoprolol on isolated feline ventricular myocytes. J Pharmacol Exp Ther 252 (1990) 1043-1052
66. Waldo A.L., Camm A.J., deRuyter H., Friedman P.L., MacNeil D.J., Pauls J.F., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348 (1996) 7-12
67. Dorian P., and Newman D. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview. Europace 2 (2000) 277-285
68. Vanoli E., Priori S.G., Nakagawa H., Hirao K., Napolitano C., Diehl L., et al. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 25 (1995) 1609-1614
69. Cheng J., Kamiya K., and Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 19 (2001) 152-171
70. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49 (2001) 361-370
71. Cheng J., Niwa R., Kamiya K., Toyama J., and Kodama I. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur J Pharmacol 376 (1999) 189-201
72. Li X., Huang C.X., Jiang H., Cao F., and Wang T. The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. Chin Med J (Engl) 118 (2005) 377-382
73. Maltsev V.A., Sabbab H.N., and Undrovinas A.I. Down-regulation of sodium current in chronic heart failure: effect of long-term therapy with carvedilol. Cell Mol Life Sci 59 (2002) 1561-1568
74. de Groote P., Delour P., Lamblin N., Dagorn J., Verkindere C., Tison E., et al. Effects of bisoprolol in patients with stable congestive heart failure. [in French]. Ann Cardiol Angeiol (Paris) 53 (2004) 167-170
75. Colucci W, Kolias TJ, Adams KF, Armstrong WF, Ghali JK. Metoprolol Reverses Left Ventricular Remodeling in Patients with Asymptomatic Systolic Dysfunction: The REVERT Trial. (Presented at the 9th annual Scientific Meeting of the Heart Failure Society of America, September 18-21, 2005, Boca Raton, FL). J Card Fail 2006;11:720.
76. Metra M., Nardi M., Giubbini R., and Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 1678-1687
77. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., and Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 29 (1997) 1060-1066
78. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., White M., Mealy P., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94 (1996) 2817-2825
79. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 92 (1995) 212-218
80. Lowes B.D., Gill E.A., Abraham W.T., Larrain J.R., Robertson A.D., Bristow M.R., et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83 (1999) 1201-1205
81. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et-al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Website. Available at http://www.acc.org/clinical/guidelines/failure/index.pdf; 2005.
82. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90 (1994) 1765-1773
83. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 349 (1997) 375-380
84. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
85. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
86. Torp-Pedersen C. Effects of metoprolol and carvedilol on cause-specific mortality in chronic heart failure patients. The Carvedilol or Metoprolol European Trial. Am Heart J 149 (2005) 370-376
87. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
88. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 106 (2002) 2194-2199
89. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
90. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342 (1993) 1441-1446
91. Lanza G.A., Guido V., Galeazzi M.M., Mustilli M., Natali R., Ierardi C., et al. Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol 82 (1998) 1323-1328
92. Maggioni A.P., Zuanetti G., Franzosi M.G., Rovelli F., Santoro E., Staszewsky L., et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 87 (1993) 312-322
93. McMurray J., Kober L., Robertson M., Dargie H., Colucci W., Lopez-Sendon J., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
94. Metra M., Torp-Pedersen C., Swedberg K., Cleland J.G.F., Di Lenarda A., Komajda M., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005) 2259-2268
95. Bristow M.R., Larrabee P., Minobe W., Roden R., Skerl L., Klein J., et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 19 Suppl1 (1992) S68-S80
96. Arumanayagam M., Chan S., Tong S., and Sanderson J.E. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 37 (2001) 48-54
97. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
98. Flather M.D., Shibata M.C., Coats A.J., van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
99. Chen L., El Sherif N., and Boutjdir M. Alpha 1-adrenergic activation inhibits beta-adrenergic-stimulated unitary Ca2+ currents in cardiac ventricular myocytes. Circ Res 79 (1996) 184-193
100. Molina-Viamonte V., Anyukhovsky E.P., and Rosen M.R. An alpha-1-adrenergic receptor subtype is responsible for delayed after depolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation 84 (1991) 1732-1740
101. Murray K.T., Hu N.N., Daw J.R., Shin H.G., Watson M.T., Mashburn A.B., et al. Functional effects of protein kinase C activation on the human cardiac Na+ channel. Circ Res 80 (1997) 370-376
102. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Cas L.D. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
103. Fonarow G.C., Chelimsky-Fallick C., Stevenson L.W., Luu M., Hamilton M.A., Moriguchi J.D., et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 19 (1992) 842-850
104. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
105. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993) 821-828
106. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
107. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
108. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
109. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991) 293-302
110. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 327 (1992) 685-691
111. Domanski M.J., Exner D.V., Borkowf C.B., Geller N.L., Rosenberg Y., and Pfeffer M.A. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta- analysis of randomized clinical trials. J Am Coll Cardiol 33 (1999) 598-604
112. Exner D.V., Dries D.L., Waclawiw M.A., Shelton B., and Domanski M.J. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33 (1999) 916-923
113. Nagele H., Bohlmann M., Eck U., Petersen B., and Rodiger W. Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur J Heart Fail 2 (2000) 71-79
114. Kadish A., Dyer A., Daubert J.P., Quigg R., Estes N.A., Anderson K.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
115. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
116. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., and Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 (1999) 1882-1890
117. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
118. Greenberg H., Case R.B., Moss A.J., Brown M.W., Carroll E.R., and Andrews M.L. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 43 (2004) 1459-1465
119. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
120. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., de Marco T., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
121. Vyas A.K., Guo H., Moss A.J., Olshansky B., McNitt S.A., Hall W.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
122. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, et al. Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy: A DEFINITE Substudy. Presented at: The Heart Rhythm Society 2006 Annual Scientific Sessions; Boston, MA: 2006.
123. Carson P., Anand I., O'Connor C., Jaski B., Steinberg J., Lwin A., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 (2005) 2329-2334